📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
GLP-1 Receptor Agonist Once-Weekly Injection

Semaglutide

Ozempic · Wegovy · Rybelsus · GLP-1 RA

"The most consequential peptide drug of the 21st century. 15% average body weight loss, 20% cardiovascular event reduction, and emerging evidence across Alzheimer's, addiction, kidney disease, and sleep apnoea. The SELECT trial changed how medicine thinks about obesity."

Type
31 aa GLP-1 analogue · C18 fatty acid + albumin binding
Half-life
~7 days · once-weekly SubQ
Status
UK: prescription only medicine (Wegovy, Ozempic, Rybelsus) · WADA: not specifically listed · US FDA: approved 2017 (T2D), 2021 (obesity), 2024 (cardiovascular risk) · MHRA-licensed
Weight loss
~15% body weight (STEP-1 trial)
Protocol summary
Weight dose
0.25 → 2.4 mg/wk SubQ
T2D dose
0.25 → 1.0 mg/wk SubQ
Titration
~16 weeks to maintenance
Clinical-labelled
Wegovy (obesity): 0.25 → 2.4 mg/wk · Ozempic (T2D): 0.25 → 1.0 mg/wk
UK access via NHS or licensed private prescriber; do not use unverified compounded versions
How we read the evidence
FDA-approved as Wegovy (obesity) and Ozempic (T2D) · 14.9–17.4% mean weight loss in STEP trials · 20% reduction in major CV events in SELECT · the most clinically validated weight-loss peptide currently available
Animal evidence

Extensive preclinical foundation. Semaglutide is a long-acting GLP-1 receptor agonist with structural modifications (Aib at position 8, fatty acid attachment at position 26) extending half-life to ~7 days for weekly subcutaneous dosing. Mechanism: agonism of GLP-1 receptors in pancreatic β-cells (insulin secretion), hypothalamic appetite circuits (satiety, reduced caloric intake), gut motility neurons (gastric-emptying delay), and cardiovascular tissue (mechanism contributing to the SELECT CV signal). Decades of GLP-1 receptor pharmacology preceded semaglutide's specific development.

Community & clinical practice

Two distinct dosing frameworks. Weight management (Wegovy): titrate from 0.25 mg weekly over 16 weeks to maintenance 2.4 mg weekly SubQ. T2D (Ozempic): titrate to maintenance 0.5–1.0 mg weekly. Titration is for GI tolerance — nausea, vomiting, constipation are most common in the titration phase and reduce with body adaptation. Find minimum effective dose — many users land below the trial maximum. Discontinuation typically causes weight regain, so plan for long-term use rather than cycles. Compounded versions exist in markets where pharmacy-grade is restricted by cost or supply; quality varies, and authenticity concerns are real (counterfeit versions in unregulated channels). Oral semaglutide (Rybelsus) is FDA-approved at 7–14 mg/day for T2D — substantially less weight effect than injectable.

Human trial data

The most clinically validated weight-loss peptide currently available. STEP program (Phase 3, 8 trials): STEP 1 (NEJM 2021) — mean weight loss −14.9% at 68 weeks vs −2.4% placebo (n=1,961, no T2D). STEP 3 — −16.0% with intensive behaviour therapy. STEP 4/5 — sustained loss at 68/104 weeks (−17.4% / −15.2%). STEP 2 — −9.6% in T2D population (smaller effect than non-T2D). Across STEP 1/3/4/8, semaglutide produced 14.9–17.4% mean weight loss; 69–79% achieved ≥10% loss; 51–64% achieved ≥15% loss. SELECT trial (NEJM 2023) — 17,604 adults with prior CV disease, overweight/obesity, no diabetes: 20% reduction in major adverse cardiovascular events, weight loss sustained up to 4 years. SUSTAIN program for T2D earlier established the diabetes evidence base.

Regulatory status

FDA-approved as Ozempic (SubQ for T2D, 2017), Rybelsus (oral for T2D, 2019), and Wegovy (SubQ for obesity, 2021). EMA and MHRA approved across these indications. Boxed warning: thyroid C-cell tumour risk (rodent data; human relevance uncertain) — contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2. Other safety considerations: pancreatitis, gallbladder disease, hypoglycaemia (with insulin/sulfonylureas), acute kidney injury from GI dehydration, gastroparesis cases under FDA review, suicidality signal investigated and not confirmed. Long-acting nature means side effects can persist for weeks after discontinuation.

Convergence

Semaglutide is the most clinically validated weight-loss peptide currently available — extensive Phase 3 program, large CV outcomes trial showing 20% MACE reduction, multiple FDA-approved indications, and a coherent dosing framework. Standard protocols: titrate to 2.4 mg weekly for weight, 0.5–1.0 mg weekly for T2D, weekly SubQ, long-term continuous use. Pep IQ flags this honestly: this is a legitimate, well-evidenced, well-titrated medicine — and it's also the standard against which newer agents (tirzepatide, retatrutide, cagrisema) are now measured. Tirzepatide produces somewhat larger weight effects in head-to-head; retatrutide Phase 2 data exceeds it again. Semaglutide remains the right starting choice for most cases requiring GLP-1 therapy because of the depth of the evidence base and the maturity of the safety profile.

Origin & Background

The drug that changed everything

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk — a synthetic analogue of human GLP-1 modified with a C18 fatty acid chain that enables albumin binding, extending its half-life to approximately 7 days and allowing once-weekly dosing. It was first approved by the FDA in December 2017 as Ozempic for type 2 diabetes. The higher-dose weight management formulation (2.4mg) was approved in June 2021 as Wegovy.

The STEP-1 trial (2021) changed the conversation: 68 weeks of semaglutide 2.4mg produced average weight loss of 14.9% of body weight in people with obesity — an effect size previously only achievable with bariatric surgery. The SELECT trial (2023) then demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in people with cardiovascular disease and obesity but without diabetes — leading to FDA approval of a cardiovascular risk reduction indication for Wegovy in March 2024.

An oral formulation (Rybelsus) is approved for type 2 diabetes, though its bioavailability is lower than injectable. Semaglutide has become one of the most prescribed drugs in history, with over 9 million monthly prescriptions in the US by mid-2025. The drug has also been investigated — with promising results — for Alzheimer's disease, addiction, kidney disease, liver disease (MASH), sleep apnoea, and heart failure.

The SELECT finding: The cardiovascular benefit from semaglutide emerged before significant weight loss and persisted in subgroups with modest weight reduction — suggesting mechanisms beyond caloric deficit, including direct anti-inflammatory effects and GLP-1 receptor activation in cardiovascular tissue. This was the finding that elevated semaglutide from a weight drug to a cardiovascular drug.

Science & Mechanism

GLP-1 — the gut-brain axis

Mechanism of Action

1
GLP-1R agonism in the hypothalamus: Semaglutide activates GLP-1 receptors in the arcuate nucleus and other hypothalamic regions, reducing hunger signals and increasing satiety. This is the primary appetite-suppression mechanism — food becomes less rewarding and portion sizes naturally decrease.
2
Gastric emptying slowing: GLP-1R activation delays gastric emptying, prolonging the feeling of fullness after eating and reducing post-meal blood glucose spikes. This contributes to both weight loss and glycaemic control.
3
Pancreatic insulin regulation: Glucose-dependent stimulation of insulin secretion and suppression of glucagon — the mechanism behind its type 2 diabetes efficacy. Does not cause hypoglycaemia when used alone because the insulin effect is glucose-dependent.
4
Cardiovascular effects: GLP-1 receptors in the heart and vasculature mediate direct cardioprotective effects — reduced inflammation, improved endothelial function, and cardiac protection independent of weight loss. Explains the SELECT cardiovascular benefit.
5
Neuroprotective / addiction signals: GLP-1 receptors in the brainstem and mesolimbic system may modulate dopamine reward pathways — potentially explaining emerging evidence for benefit in addiction, Alzheimer's, and other neurological applications.
Benefits & Evidence

What the data shows

⚖️
Weight loss — clinically significant
STEP-1 trial: 14.9% average body weight loss at 68 weeks with semaglutide 2.4mg vs 2.4% placebo. 50% of participants lost more than 15% of body weight. Weight regain occurs rapidly after stopping — maintenance therapy is required. The most effective non-surgical weight loss intervention ever approved.
● Strong — multiple Phase III RCTs
🫀
Cardiovascular risk reduction
SELECT trial (n=17,604): 20% relative risk reduction in major adverse cardiovascular events over 34 months in people with CVD and obesity without diabetes. FDA approved this indication in March 2024 — the first obesity drug approved for CV risk reduction. Effect independent of weight loss degree.
● Strong — landmark RCT · FDA approved
🩸
Type 2 diabetes glycaemic control
SUSTAIN programme: HbA1c reductions of 1.0–1.8% alongside weight loss. Superior to most other diabetes medications including older GLP-1 agonists. Ozempic approved 2017, established as a first-line T2D agent in major guidelines.
● Strong — multiple RCTs · FDA approved
🧠
Neurological — addiction, Alzheimer's (emerging)
Observational data shows reduced alcohol and drug cravings. A 2024 placebo-controlled trial showed semaglutide reduced alcohol consumption by 40%. Phase III Alzheimer's trials ongoing with positive signals from observational studies. Genuinely exciting but not yet established.
● Emerging — trials ongoing
💤
Sleep apnoea
SURMOUNT-OSA trial (2024): semaglutide reduced obstructive sleep apnoea severity by ~20 events/hour — a clinically meaningful improvement. FDA approved tirzepatide for sleep apnoea in 2024; semaglutide applications ongoing.
● Moderate — Phase III data
Things to know

Risks & considerations

⚠️
Well-characterised profile with important long-term unknowns. Semaglutide has the largest clinical trial evidence base of any peptide in this book. GI side effects dominate the short-term. Muscle loss and long-term thyroid/pancreatic effects are the most important ongoing safety questions.
Moderate
Nausea, vomiting, diarrhoea — the most common class effect. Occurs in 40–50% of users, typically during dose escalation. Usually improves after 4–8 weeks at a stable dose. Managed by slow titration.
Moderate
Muscle loss — studies suggest 25–40% of weight lost may be lean mass without resistance training. This is not mentioned prominently enough in prescribing practice. Non-negotiable requirement: resistance training + adequate protein during any GLP-1 protocol.
Moderate
Nutrient deficiencies — reduced appetite means reduced nutrient intake. B12 (impaired gastric absorption), calcium, iron and vitamin D are the most common deficiencies. Supplementation is recommended.
Serious
Pancreatitis risk — rare but serious. History of pancreatitis is a relative contraindication. Severe abdominal pain during treatment warrants immediate medical evaluation.
Serious
Thyroid C-cell tumours (rodent data) — medullary thyroid cancer observed in rodents at high doses. No confirmed human cases, but contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2.
Serious
Rapid weight regain on stopping — most users regain the majority of lost weight within 1–2 years of cessation. This should be framed as a chronic medication, not a course of treatment.

⚠ Key Warnings

Resistance training and 1.2–1.6g/kg protein daily is not optional — it is the most important co-intervention to prevent muscle wasting during GLP-1 weight loss.
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN type 2.
Not a short-term intervention — weight regain is near-universal after stopping. The conversation before starting must include long-term plans.
Compounded semaglutide was widely available during US drug shortages but the FDA has restricted this as the shortage resolved. Verify legal status in your jurisdiction.